RBC Capital Maintains Outperform on Biogen, Raises Price Target to $363
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) and raised the price target from $351 to $363.
November 09, 2023 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's price target has been raised from $351 to $363 by RBC Capital, maintaining an 'Outperform' rating.
The news of RBC Capital maintaining an 'Outperform' rating on Biogen and raising the price target is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100